MarketInOut Stock Screener Log In | Sign Up
 

Avalyn Pharma Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Avalyn Pharma Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,146.01 mln
Float26.64 mln
Earnings Date11/16/2026

1-Year Forecast

61.80
Transformational upside

Relative Strength

75 / 100
Strongly outperforming

Debt / Equity

0.04
Debt-free

ROE

-22.04
Deeply negative

ROA

-19.89
Deeply negative

Business Description

Avalyn Pharma is a Boston-based clinical-stage company working to improve treatment for rare lung diseases, particularly pulmonary fibrosis. Rather than relying on pills, the company delivers established medications directly to the lungs through inhalation, aiming to make them more effective and better tolerated. Its lead programs include inhaled versions of two proven drugs, as well as a combination therapy that targets the disease through two different pathways at once.

Key Fundamentals

EPS-2.47
ROE-22.04
ROIC-144
ROA-19.89
Interest Cover-160
EBITDA, mln-55.26
EV / EBITDA-16.87
EV / EBIT-16.82

Quote Details

Last 26.04
Change -1.21 (-4.44%)
Open 27.21
Volume 318,175
Turnover 8,285,278
Average Volume 316,793

Financial Ratios

Leverage Ratio1.07
Current Ratio33.10
Price / Book3.18
Price / Tangible Book3.18
Debt / Equity0.04

Financial Strength

1-Year Target Price61.80
Short Ratio9.45
Short % of Float5.68

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 10.06% 95 / 100   
1 Month -8.79% 32 / 100   
2 Months -9.05% 33 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog